Role of IL-6 in shaping local immune milieus in the CNS

A07

IL-6 is increasingly identified as therapeutic target for a variety of inflammatory human diseases including Multiple Sclerosis. Due to the complexity of IL-6 directed interventions and differential responses of the distinct IL-6 signaling modalities to therapies, we now set out to investigate responses to IL-6 in the CNS in detail. We will assess the most relevant sources of IL-6 in the CNS, address the role of IL-6 signaling into conventional T cells and Foxp3+ Treg cells in the CNS during autoimmune inflammation, and finally study the impact of IL-6 on the formation of unique Treg cell niches during recovery from EAE.

Within the upcoming years we will tackle the following questions:

    1. Is continuous sensing of IL-6 required in order to maintain the encephalitogenicity (survival) of Th17 cells?
    2. Can CCR2+ myeloid cells and (to a lesser extent) B cells provide IL-6 signalling?
    3. Can molecules that are suppressed by IL-6 be used as biomarker to predict progressive disease in MS patients?

 

Heink et al., Nat Immunol., 2017

 

Principal Investigators:

Univ.-Prof. Dr. rer. nat. Ari Waisman
Institut für Molekulare Medizin
Mainz
waisman@uni-mainz.de

Univ.-Prof. Dr.med. Thomas Korn
Neurologische Universitätsklinik
TU München
thomas.korn@tum.de

News

Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more
Wed, 20/01/2021
A new study on neurological manifestations of severe COVID-19 reveals nervous system immune deficiency
Patients suffering from COVID-19 can develop concomitant and long-term symptoms in their nervous system. The most common symptom in this context is the loss of the sense of smell and taste, while more severe symptoms such as stroke, cerebral seizures, or meningitis are possible. A team of scientists from the medical faculties at the Universities […]...more